摘要
目的探索VATS肺叶切除术治疗早期肺癌的临床效果。方法方便选取该院2016年8月—2020年8月收治的200例早期肺癌患者,随机分两组。对照组100例采取开胸肺叶切除术,观察组100例患者则实施VATS肺叶切除术。比较两组患者术中出血量、手术时间、住院时间、并发症发生率、手术前后肺癌患者生存质量测定量表(FACT-L)评分。结果观察组术中出血量、手术时间、住院时间为(45.21±12.01)mL、(121.34±5.01)min、(6.26±0.25)d低于对照组,差异有统计学意义(t=24.294、18.164、11.248,P<0.05)。观察组并发症发生率为2.00%低于对照组的18.00%,差异有统计学意义(χ^(2)=14.222,P<0.05)。观察组手术后患者FACT-L评分均优于对照组,差异有统计学意义(P<0.05)。结论早期肺癌患者实施VATS肺叶切除术效果确切,可更好地减少并发症和改善生存质量,是一种有效治疗肺癌的方式,在患者具备手术指征的情况下,值得推广和应用。
Objective To explore the clinical effect of VATS lobectomy in the treatment of early lung cancer.Methods A Selected conveniently 200 patients with early-stage lung cancer from August 2016 to August 2020 admitted to the hospital were enrolled and randomly divided into two groups.100 patients in the control group underwent thoracotomy lobectomy,and 100 patients in the observation group underwent VATS lobectomy.The intraoperative blood loss,operation time,hospital stay,complication rate,and FACT-L scores were compared between the two groups of patients.Results The intraoperative blood loss,operation time,and average hospital stay of the observation group were(45.21±12.01)mL,(121.34±5.01)min,(6.26±0.25)d lower than those of the control group,the difference was statistically significant(t=24.294,18.164,11.248,P<0.05).Complications in the observation group were 2.00%lower than 18.00%in the control group,the difference was statistically significant(χ^(2)=14.222,P<0.05).The FACT-L scores of patients in the observation group after surgery were better than those in the control group,the difference was statistically significant(P<0.05).Conclusion The effect of VATS lobectomy in patients with early lung cancer is definite,which can better reduce complications and improve the quality of life.It is an effective way to treat lung cancer.It is worthy of promotion and application when the patients have surgical indications.
作者
李旭
张邦辉
张永聪
吴健
LI Xu;ZHANG Banghui;ZHANG Yongcong;WU Jian(Department of Thoracic Surgery,Quanzhou First Hospital,Fujian Medical University,Quanzhou,Fujian Province,362000 China)
出处
《中外医疗》
2021年第28期56-59,共4页
China & Foreign Medical Treatment
